goodtoknow says: Macular degeneration is the most common cause of serious vision problems, but there are promising new treatments now. It happens because tiny cells in your eye get damaged and die. There are two types of macular degeneration. Dry ARMD is the cause in 9 in 10 cases and can make reading, writing, driving and recognising faces increasingly difficult, although this can take many years. Wet ARMD is much quicker but rare. Both mainly affect older people, women more than men. Around 1 in 8 people over 85 have it.
For a full medical explanation of the causes, symptoms and treatments of macular degeneration from patient.co.uk, read on.
Age-related macular degeneration (ARMD) causes a gradually loss of central vision, but not peripheral vision. Central vision is needed for reading, driving, recognising faces and doing detailed work. The decline to severe loss of vision can vary from months to years - depending on the type and severity of ARMD. Visual loss caused by ARMD cannot be reversed. However, in a small number of cases, treatment may halt or delay the progression of visual loss.
When you look at an object, light from the object passes through the cornea, then the lens, and then hits the retina at the back of the eye.
When you look at an object, the light from the object focuses on the macula. You need a healthy macula for detailed central vision such as when reading, writing, driving and recognising faces. The rest of the retina is used for peripheral vision - the 'side' vision which is not focussed. Therefore, without a macula you can still see enough to get about, be aware of objects and people, and be independent. However, the loss of central vision will severely affect normal sight.
Age-related macular degeneration (ARMD) is a condition that occurs when cells in the macula degenerate. That is, they become damaged and die. Damage to the macula affects your central vision which is needed for reading, writing, driving, recognising people's faces and doing other fine tasks. There are two types - 'dry' and 'wet' ARMD - described below.
ARMD is the most common form of macular degeneration and develops in older people. (There are other rare types of macular degeneration which occur in younger people.) ARMD can affect anyone. It is the most common cause of severe sight problems ('visual impairment') in the UK. It becomes more common with increasing age. If you develop ARMD in one eye, you have a high chance that it will also develop in the other eye.
About 1 in 100 people aged 65-75, and about 1 in 8 people aged over 85 have ARMD severe enough to cause serious visual loss. About twice as many women over the age of 75 have ARMD compared to men of the same age.
The two types of age-related macular degeneration
This is the most common form and occurs in 9 in 10 cases. In this type the cells in the retinal pigment epithelium of the macula gradually become thin (they 'atrophy') and degenerate. This layer of cells is crucial for the function of the rods and cones (the 'seeing cells') which then also degenerate and die. Typically, dry ARMD is a very gradual process as the number of cells affected increases. It usually takes several years for vision to become seriously affected. Many people with dry-ARMD do not totally lose their reading vision.
This occurs in about 1 in 10 cases. However, it is likely to cause severe visual loss over quite a short time - sometimes just months. In this type of ARMD, in addition to the retinal pigment cells degenerating, new tiny blood vessels grow from the tiny blood vessels in the choroid. (This is called 'choroidal neovascularisation'.) The new vessels break through Bruch's membrane and into the macular part of the retina. These vessels are not 'normal'. They are fragile and tend to leak blood and fluid. This can damage the rods and cones, and cause scarring in the macula.
In people with ARMD the cells of the retinal pigment epithelium do not work so well with advancing age. They gradually fail to take enough nutrients to the rods and cones, and do not clear waste materials and 'by-products' very well made by the rods and cones. As a result, tiny abnormal deposits called 'drusen' develop under the retina. In time the retinal pigment cells and their nearby rods and cones degenerate, stop working and die. This is the 'dry' type of ARMD.
In some cases, something also triggers new blood vessels to develop from the choroid to cause the 'wet' form of ARMD. The trigger is not known. It may be that some waste products which are not cleared from the retinal pigment epithelium may stimulate new blood vessels to grow in an attempt to clear the waste. The exact reason why cells of the retinal pigment epithelium stop working properly in people with ARMD is not known. Certain 'risk factors' increase the risk of developing ARMD. These include:
ARMD is painless. Symptoms of dry-ARMD tend to take 5-10 years to become severe. However, severe visual loss due to wet-ARMD can develop over weeks or months. Therefore, see a doctor or optometrist quickly if you develop visual loss or visual distortions as treatment may be possible. Peripheral vision is not affected with ARMD and so it does not cause total blindness.
Note: if the vision of one eye only is affected, you may not notice any symptoms as the other good eye often compensates. When both eyes are affected you are more likely to notice symptoms. Therefore, older people should have regular eye checks to check on each eye separately for early ARMD (and to check for other eye conditions such as glaucoma.)
If you develop symptoms suggestive of ARMD your doctor or optometrist will refer you to an eye specialist (ophthalmologist). The specialist may ask you to look at a special piece of paper with horizontal and vertical lines. If you find that any section of the lines are missing or distorted then ARMD is a likely cause of the visual problem. The ophthalmologist will examine the back of your eye with a magnifier. There are typical changes that occur with dry-ARMD and wet-ARMD which can often be seen.
If wet-ARMD is diagnosed or suspected, then a further test called fluorescein angiography may be done. For this test a dye is injected into a vein in your arm. Then, by looking into your eyes with a magnifier and taking pictures with a special camera, the ophthalmologist can see where any dye leaks into the macula from the abnormal leaky blood vessels. This test can give an indication of the extent and severity of the condition.
Another test called ocular coherance tomography is becomming more commonly used. This is a non-invasive test that uses special light rays to 'scan' the retina. It can give very detailied information about the macula, and show if the macula is thickened or abnormal. This test is useful when there is doubt about wheter AMD is the wet or dry form. It is also a useful test to assess the result of any treatment.
This is a technique that was developed in the late 1990s. A drug called verteporfin is injected into a vein on the arm. Within a few minutes the verteporfin binds to proteins in the newly formed abnormal blood vessels in the macula. A light at a special wavelength is then shone into the eye for just over a minute. Verteporfin is a photosensitive drug. This means that when light is shone at the blood vessels coated with verteporfin, the verteporfin 'activates' and causes damage and destroys the abnormally growing blood vessels (without damaging the nearby rods and cones).
Photodynamic therapy is only suitable for some cases. It depends on exactly where the new blood vessels are growing and their extent. It does not work in all cases although the success rate in treated people is high. success means that the visual loss is prevented from getting worse - it does not resore any lost vision. Treatment usually needs to be repeated every few months to continue to suppress newly growing blood vessels.
In recent years a group of drugs (medicines) called anti-VEGF drugs have been developed. VEGF stands for 'Vascular Endothelial Growth Factor'. This is a chemical that is involved in the formation of new blood vessels in the macuala in people with wet-ARMD. By blocking the action of this chemical, it helps to prevent the formation of tha abnormal blood vessels that occur in wet-ARMD.
Anti-VEGF drugs include ranibizumab (trade name, Lucentis), pegaptanib (Macugen), and bevacizumab (Avastin). Others are being developed. These drugs are injected directly into the vitreous of the eye by a fine needle, and injections are needed every few seeks to keep on with their effect. Anti-VEGF drugs are an exciting new development in the treatment of ARM as they seem to work reasonably well for all types of wet-ARM. For example, one study of 716 people treated with ranibizumab (published in the New England Journal of Medicine in October 2006) found that the treatment slowed visial loss in around 9 in 10 people, and improved vision in about a third.
So, the main aim of treatment with Anti-VEGF drugs is to prevent wet-ARMD from getting worse. However, it seems that in some cases these drugs may actually restore some of the vision that has been lost.
It is likely that anti-VEGF drugs will become more widely used. The National Institute for Health and Clinical Excellence in the UK is currently appraising pegaptanib and ranibizumab to claify their role and use in the NHS. Their report is expected in September 2007.
This is a technique where a fine laser is 'fired' at the tiny new blood vessels that are forming. This destroys the blood vessels which helps to prevent the condition from getting worse. ?
However, laser photo-coagulation is only suitable for a small number of cases. Whether it is suitable depends on exactly where the new blood vessels are growing as the laser may also damage the rods and cones.
Treatments such as radiation therapy, other drugs, and surgery to the retina are being investigated. For example, a surgical tecnique where a part of the peripheral retina is grafted into the diseased macular area is being investigated. The value of these newer treatments is not clear. The treatmnet of macular degeneration is an active area of research and treatment may well improve in the near future.
A recent large research trial aimed to clarify whether diet and dietary supplements had a role to play in the treatment of ARMD. It was called the 'Age-Related Eye Disease Study' (AREDS). This showed that in some cases, high quantities of dietary supplements that contain the antioxidant vitamins A, C, E, beta-carotene and the minerals zinc and copper, can help to slow down the progression of ARMD. The study suggests that people at high risk for developing advanced ARMD should consider taking theses dietary supplements. People at high risk are defined as people having either:
The supplements taken should only be those recommended by your doctor or eye specialist. This is because some supplements that are marketed to the general public for ARMD do not contain to correct doses. Also, there is some concern that the high doses needed may lead to side effects in some people. For example, beta-carotene has been found to increase the risk of lung cancer in smokers; vitamin E has been associated with an increased risk of heart failure in people with vascular disease or diabetes; zinc may increase your risk of developing bladder and kidney problems. (So, for example, the supplements are probably not suitable for current or ex smokers due to the increased risk of developing lung cancer).
In short: before taking these high doses of vitamins and minerals, you should talk with your doctor about the risk of developing advanced AMD and whether taking the these high dose supplements is right for you.
Research continues to clarify the role of diet and dietary supplements.
When your vision becomes poor, it is common to be referred to a low vision clinic. Staff at the clinic provide practical help and advice on how to cope with poor vision. For example, advice about:
The Macular Disease Society
Darwin House, 13a Bridge Street, Andover, Hampshire, SP11 6NN?Tel: 0845 241 2041 Web: www.maculardisease.org
Comprehensive patient resources are available at www.patient.co.uk
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS and PiP have used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.
© EMIS and PiP 2007 Updated: 9 May 2007 DocID: 4860 Version: 38